-
Sunitinib, sold
under the
brand name Sutent, is an anti-cancer medication. It is a small-molecule, multi-targeted
receptor tyrosine kinase (RTK) inhibitor...
-
effectiveness of
everolimus in
carcinoid tumors have not been established.
sunitinib (Sutent) is
labeled for
treatment of progressive, well-differentiated...
-
cytokine therapy (IL-2, interferon),
kinase inhibitors (temsirolimus,
sunitinib, sorafenib, pazopanib) and anti-angiogenic
therapies (bevacizumab). "Clear...
-
kinases as
therapeutic targets and
developing the
successful cancer therapy sunitinib (Sutent).
Sugen was
founded in 1991 in
Redwood City, California, by veteran...
-
small molecules that
inhibit the
tyrosine kinases stimulated by VEGF:
sunitinib, sorafenib, axitinib, and
pazopanib (some of
these therapies target VEGF...
- by Pfizer. It was
developed by
SUGEN as SU11654, a
sister compound to
sunitinib,
which was
later approved for
human therapies.
Toceranib is
likely to...
- (NSCLC).
Sunitinib is an oral drug that
inhibits the
phosphorylation of all the VEGF receptors, PDGFR-ß, KIT FLT3, CSF1R and GDNF.
Sunitinib is used in...
-
randomized study of
zanzalintinib in
combination with
nivolumab versus sunitinib in
patients with
advanced or
metastatic non-clear cell RCC (nccRCC). Sharma...
- MedlinePlus.
Clinical trial number NCT01835158 for "Cabozantinib-s-malate or
Sunitinib Malate in
Treating Patients With
Previously Untreated Locally Advanced...
-
Retrieved 20 July 2023. "A
Study of
Abemaciclib in
Combination With
Sunitinib in
Metastatic Renal Cell Carcinoma". www.clinicaltrials.gov. Retrieved...
